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tions into the sixth decade. 4 Since the introduction of years of age, participated. The group included 5 paphototherapy during the early 1970s, 5 most patients surtients with type I disease who were all treated with phototherapy and 6 patients with type II disease who vive childhood, but development of neurological disorwere primarily treated with phenobarbital. In addition ders at a later age has been described. 6 In The Netherto plasma bilirubin levels, dietary intake and urinary lands, 19 patients with this disease are known, 9 of them and fecal excretion of calcium and phosphate were with type I and 10 with type II disease. The patients evaluated. Results: A modest but significant decrease with type I disease (age, 1-22 years) are treated with in serum bilirubin was observed in patients with type I home phototherapy for 8-12 h/day, and those with type disease (18% { 6%, P Å 0.03) but not in patients with Despite the fact that the immediate risk of kernicterus and death is greatly diminished since the introduction of phototherapy, a lot of problems remain for the pa-C tients. For instance, all type I patients have skin problems rigler-Najjar disease, first described in 1952, 1 is an autosomal recessive inherited disorder caused caused by the phototherapy. The skin is fragile, easily by a deficiency of bilirubin-uridine 5-diphosphateinjured, and heavily pigmented despite the fact that only glucuronosyltransferase (bUGT) in the liver. Patients affected by this disease have unconjugated hyperbilirubi-The effect of 100 mmol calcium (50 mmol CaCO 3 and 50 blue light is used. The long-term effects of phototherapy mmol CaHPO 4 r2H 2 O)/day in adult patients with Criglerare unknown, but it has been described that DNA dam-Najjar disease was investigated. Children (õ40 kg body wt) age is induced in human cells exposed to phototherapy received 2.5 mmol calcium/kg body wt. The molar ratio of light, and this effect is enhanced by bilirubin. 7 These carbonate vs. phosphate was identical in adults and children. patients cannot live away from home because they need daily phototherapy. Furthermore, although the sedative Patients effect of phenobarbital in many patients is transient, Eighteen patients and their parents received written some patients with type II disease complain of lethargy and oral information about the trial and were asked to particiand diminished mental activity. In addition, phenobarbipate in the study. A 1-year-old patient was excluded. The tal affects other enzymes in the liver, such as cytochrome only other exclusion criterion was impaired renal function as P450s, and thereby influences the metabolic breakdown determined by a serum creatinine above the age-dependent of drugs and nutrients. normal value. All patients had normal renal function. Reasons Gunn rats and patients with Crigler-Najjar disease for withdrawal were an increase in plasma bilirubin level above excrete normal amounts of bilirubin and bilirubin break- of bilirubin. The feasibility of this approach has been years, the parents gave informed consent. In patients 1-9, the proven in Gunn rats, the animal model for Criglertrial was performed during spring (April to June) and in pa-Najjar disease. Oral administration of 5% (wt/wt) actitients 10 and 11 during autumn (September to November).
vated charcoal decreases bilirubin levels by approximately
Study Design 40%. 13 Aspecific binding of a broad range of organic and inorganic compounds renders the applicability of A placebo-controlled, double-blind, crossover study activated charcoal impossible for prolonged use. We have was performed. Cellulose was used as placebo because, in Gunn rats, a diet containing 40% (wt/wt) Cellulose had no effect on reported that UCB binds to amorphous calcium phosplasma bilirubin levels (unpublished results, December 1991 phate (ACP) in vitro 14 ; in line with this, we have demonto February 1992). strated that oral supplementation of calcium phosphate The duration of the trial was 10 weeks. The usual therapy reduces the plasma bilirubin levels in Gunn rats. 15 The was continued. Blood was collected by venipuncture once a dose of calcium (administered as calcium phosphate)
week. The intraindividual variation in plasma bilirubin level needed to achieve a decrease of approximately 40% was was determined in three blood samples during a control period. only four times the normal ingested amount of calcium.
During the next 3 weeks, patients ingested either the calcium Based on these results, we initiated a placebo-controlled, medication or the placebo and blood was collected three times double-blind, crossover study of the effect of oral calcium (treatment period or placebo period). The daily dosage was phosphate in 11 patients with Crigler-Najjar disease. divided into four portions and ingested with the meals and before bedtime. Then a washout period of 2 weeks without Patients and Methods treatment followed. At the end of this period, bilirubin was Medication analyzed again. Subsequently, the patients received either the placebo or the calcium medication (placebo or treatment pe-In the human gut, substantial amounts of phosphate riod). Thus all patients received one course of calcium medicaare present. As we have shown, free phosphate inhibits the tion and one course of placebo and could be used as their own binding of UCB to ACP in vitro. 14 Therefore, the phosphate control. already present in the gut should be used in the formation Patients were allowed to eat their normal diet, but the use of ACP. This can be achieved by administration of calcium of vitamin D was prohibited. Food intake was assessed three carbonate. Consumption of up to 50 mmol of calcium carbontimes, once in each period. Patients and parents were instructed ate/day leads to the formation of ACP, as has been shown by by a dietician to keep a detailed record for 3 successive days, fecal analysis of human adults receiving calcium supplementaending the first day of the weekend. During the same weekend, tion. Higher intake of calcium carbonate does not lead to the patients collected 24-hour urine and 48-hour feces, except more ACP formation. To produce more ACP in the intestine, supplementation of calcium phosphate is needed. 16 in the control period. The dietary records were coded for analy-/ 5e18$$0003 01-15-97 17:59:25 gasa WBS-Gastro sis by a dietician and nutrient intake was calculated from the hour collection of stools was diluted 1:1 with bidistilled water and homogenized. Three different samples of approximately computerized Netherlands food composition table.
Blood samples were assayed for bilirubin both in the local 1 g were taken from each collection of stool and weighed. Ten milliliters of 1 mol/L HNO 3 was added to the samples, and hospital and in our own laboratory. Directly after venipuncture, the tubes were protected from light. Bilirubin, hemoglo-the mixture was boiled for 5 minutes. The volume was adjusted to exactly 50 mL with bidistilled water and mixed. Five millili-bin, and hematocrit were analyzed within 30 minutes. The rest of the plasma was placed on dry ice and handed to the ters was removed and centrifuged at 1500g. The supernatant was analyzed for calcium and phosphate. Calcium was deter-researcher. It was analyzed further in the laboratory of the Academic Medical Center, Amsterdam, the next day.
mined by flame spectrophotometry. Phosphate analysis of the supernatant was identical to the analysis of phosphate in urine. Urine and feces were stored at 4ЊC and 020ЊC, respectively, immediately after collection and handed to the researcher Diet. The mean daily intake of calcium and phosphate was assessed by determining the intake over a period of 3 within 4 days. Urine was processed the next day, and feces were stored at 020ЊC until analyzed. Patients or parents were successive days. This was performed three times, once in each period. asked to keep a record about the frequency of bowel movements and possible side effects.
Statistical Analysis
In vitro binding of phenobarbital and estrogen to calcium phosphate was analyzed and found to be undetectable. How-Results are expressed as means { SD. For intraindividever, patients using oral contraceptives were advised to use ual differences, statistical analysis was performed using a oneadditional methods during the last 7 weeks of the trial.
way paired t test. For analysis of the group as a whole, a nonparametric paired test was performed, using the mean of
Analytical Procedures
the treatment period (n Å 3) and the mean of control values plus values in the placebo period (n Å 7) after it was shown Blood. Bilirubin, calcium, magnesium, phosphate, that the values in the placebo period were not significantly haptoglobin, hemoglobin, hematocrit, lactate dehydrogenase, different from the control values. A level of 0.05, one-tailed, sodium, potassium, urea, creatinine, and phenobarbital levels was used for significance. were determined using routine clinical chemical methods on a Hitachi 747 analyzer (Hitachi, Tokyo, Japan).
Results
Urine. Urine was acidified by adding 10 mL of 4 mol/L
The clinical parameters of the included patients HCl to the flask before collection was started. Urinary calcium, are described in Table 1 . The age of the patients ranged phosphate, creatinine, sodium, potassium, and urea were anafrom 2 to 42 years. Five patients had type I and 6 patients lyzed by standard clinical chemical methods.
Feces. After determination of wet weight, the 48-type II disease. Four patients were treated with photo- therapy, 2 with phenobarbital, and 3 with a combination amounts of calcium and phosphate during the three different periods (Table 3) . Nevertheless, the total amount of phototherapy and phenobarbital; 2 patients were not treated at all. The intensity of phototherapy differed con-of calcium ingested was three to eight times higher during the treatment period than during the placebo period siderably among the patients. The patients continued their usual therapy during the study. All 11 patients in all patients. The ingested calcium to phosphate ratio was also increased, which is favorable for the formation completed the study. Stool frequency was unchanged during the trial. The parents of patients 4 and 7 stated of amorphous calcium phosphate in the gut. Urinary output of calcium and phosphate was similar that their child protested more often against one of the two drugs, which afterward proved to be the calcium in the placebo period and the treatment period and reflects the lack of absorption of both compounds from the medication. No other complaints or side effects were mentioned. Bilirubin levels decreased in 9 of 11 patients, gut (Table 4 ). Urea and creatinine levels in urine were unaltered. Fecal output of calcium and phosphate was but the effect in individual patients reached statistical significance only in patients with type I Crigler-Najjar determined in 48-hour collections. In all patients, except patient 4, output of calcium and phosphate markedly disease ( Figure 1 and Table 2 ). In patient 4, the bilirubin level was higher during the treatment period than during increased during the treatment period and the calcium to phosphate ratio in feces increased as well, correspond-the placebo period (P Å 0.03).
The intraindividual variation in plasma bilirubin lev-ing to the intake of both compounds (Table 4) . Total recovery of ingested calcium and phosphate in els ranged from 1% to 18%. A paired nonparametric test was used to evaluate the effect of the calcium medication urine and feces varied considerably among patients (Table  5 ). During the placebo period, calcium recovery was in the type I group. A statistically significant decrease in mean plasma bilirubin level was found in the type I 103% { 31% and phosphate recovery was 90% { 26%. Overall recovery of calcium and phosphate was less dur-group during the treatment period (18% { 6%; P Å 0.03). In the type II group, no significant difference was ing the treatment period. In patient 4, recovery of calcium and phosphate was extremely low during the treat-found. No differences were observed in plasma calcium, magnesium, phosphate, haptoglobin, hemoglobin, hema-ment period. This patient therefore might have been noncompliant. tocrit, lactate dehydrogenase, sodium, potassium, urea, creatinine, and phenobarbital levels.
Discussion
As was anticipated, the dietary intake of calcium and phosphate varied among the patients, but less expected, To our knowledge, the combination of calcium carbonate and calcium phosphate that we prepared had individual patients also consumed highly different / 5e18$$0003 01-15-97 17:59:25 gasa WBS-Gastro not been administered before. Therefore, it was first eval-the significance of the observations was restricted by the fact that only 1 patient was treated in each study. We uated in 6 healthy human volunteers. This pilot trial had the opportunity to perform a trial in 11 patients focused on the best choice of preparation (capsules, suswith Crigler-Najjar disease. The normal therapeutic pension, tablets, or powdered), side effects, and tolerance. management (phototherapy or phenobarbital) had to be Calcium carbonate is often said to be a constipating continued for obvious reasons in this study. The mean agent, and this is potentially disadvantageous for bilirubin levels of the patients are relatively low under Crigler-Najjar patients because they partly dispose of this regime, which could mask the efficacy of the drug their UCB directly via the gut. No side effects were tested in this study. The trial was performed during the detected, and tolerance was good. The most acceptable same period in spring in almost all patients. During this way to ingest this amount of calcium (13.6 g calcium season, bilirubin levels are substantially lower than in salts/day in adults) proved to be the powdered form.
winter. Considering the variation in individual bilirubin A few reports have been published on the interruption levels and the limited number of patients, a placeboof the enterohepatic cycling of bilirubin by agar or controlled crossover design was selected so that each pacholestyramine 17, 18 for treatment of Crigler-Najjar distient could be used as his or her own control. Because ease. The effect was found to be at best marginal, and half of the patients received the placebo first and the calcium medication last, and the other half vice versa, phosphate induces a more efficient pathway of bilirubin prevented when bilirubin or its isomers are bound to calcium phosphate in the gut. Therefore, the differential disposal in patients with type I disease compared with type II disease. The reason for this is unclear. Patients effect of calcium phosphate treatment in patients with with type II disease excrete some bilirubin glucuronides type I and type II disease may be caused by the fact that in bile, and in all patients but 1 in this subgroup, this type I patients undergo extensive phototherapy and thus pathway was stimulated by phenobarbital treatment.
excrete UCB (in the form of isomers), whereas type II Conjugated bilirubin is not reabsorbed in the gut. 10, 11 patients excrete conjugated bilirubin. If this hypothesis On the other hand, all patients but 1 (patient 10) with is true, the effect of calcium phosphate will be related to type I disease were treated with phototherapy, which the intensity and duration of phototherapy, and calcium induces disposal of a substantial amount of bilirubin by phosphate could be used only as an adjuvant to photoexcretion of bilirubin photoproducts in the bile. Three therapy. Three patients in type II group also received different photochemical reactions of bilirubin have been phototherapy; however, therapy was much less extensive shown to occur in vivo during phototherapy: configurathan in type I group (Table 1) . Two of these patients tional isomerization, photocyclization (lumirubin forma-(patients 1 and 3) had a small but insignificant decrease tion), and photo-oxidation. 19 Only the configurational in serum bilirubin level; the third (patient 4) was probaisomers can rearrange back to bilirubin IXa, which can bly noncompliant as discussed above. diffuse back to the blood again. The latter step may be If our hypothesis is correct, a substantial amount of bilirubin should be excreted into bile in the form of configurational isomers during phototherapy. It has been during phototherapy, which may reflect the equilibrium / 5e18$$0003 01-15-97 17:59:25 gasa WBS-Gastro between formation, on one hand, and reversion and en-large quantities of Ca 2/ or Al 3/ may cause formation of large amounts of insoluble phosphate that may diminish terohepatic cycling, on the other. Our data imply that formation of configurational isomers and excretion into the net absorption of phosphate. 27 Obviously, the purpose in our trial was the formation of insoluble calcium phos-bile could contribute to bilirubin disposal during phototherapy. Apparently, this pathway is inefficient and can phate in the gut, and therefore resorption of high amounts of calcium or phosphate would be undesirable. be enhanced significantly by bilirubin trapping in the gut. In line with our data is the observation that treat-Urinary output of calcium and phosphate were similar during the placebo period and the treatment period, ment of jaundiced neonates with agar reduces the period of phototherapy required for normalization of the serum which is important because it reflects the lack of resorption of both compounds from the gut. It seems likely bilirubin level. 22, 23 Although there is no supporting evidence in our study for the assumption that the observed that it is possible to increase the dose without the development of adverse effects. It may be useful to change the decline in plasma bilirubin level was caused by enhanced fecal excretion of the pigment as a bound complex with ratio of carbonate to phosphate when higher amounts of calcium are administered because the daily intake of solid calcium phosphate, we have proven previously the correctness of this mechanism in the Gunn rat. 15 Of phosphate with the diet will be constant. course, we cannot exclude the possibility that at higher
In conclusion, oral calcium phosphate can be a useful doses of calcium phosphate, there would also be an effect adjuvant for phototherapy in patients with Criglerin patients with type II disease due to intestinal trapping Najjar type I disease. of UCB, arising from hydrolyzation of conjugated biliru-
